Biocytogen is thrilled to be heading to Basel, Switzerland for Swiss Biotech Day 2026 from May 4th - 5th. This incredible event will be a great opportunity to connect with industry professionals and explore the talent and innovation at the heart of the Swiss biotech ecosystem. Come visit booth GV20 and meet our team to learn more about Biocytogen’s fully human antibody library and off-the-shelf models.
What is Swiss Biotech Day 2026?
Swiss Biotech Day brings together industry leaders and innovators to network, share ideas, and explore the latest developments in R&D, manufacturing, AI and financing. They provide a Global Village platform for international delegations to encourage cross-border investments and collaborative research. This year’s event will feature two days of dynamic panel discussions, pitching sessions, and dedicated networking tables.
Event Overview
Date: May 4th - 5th, 2026
Venue: Congress Center Basel, Messepl. 21, 4058 Basel, Switzerland
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Basel, Switzerland!
